State of Wyoming Buys New Shares in LifeStance Health Group, Inc. $LFST

State of Wyoming bought a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 68,678 shares of the company’s stock, valued at approximately $736,000.

Several other hedge funds also recently bought and sold shares of LFST. Assetmark Inc. increased its stake in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after buying an additional 1,367 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of LifeStance Health Group by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after acquiring an additional 1,966 shares in the last quarter. Vident Advisory LLC lifted its position in shares of LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after acquiring an additional 2,447 shares in the last quarter. Xponance LLC boosted its stake in shares of LifeStance Health Group by 26.4% in the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock worth $93,000 after acquiring an additional 2,745 shares during the period. Finally, Diversified Trust Co boosted its stake in shares of LifeStance Health Group by 14.8% in the first quarter. Diversified Trust Co now owns 21,532 shares of the company’s stock worth $137,000 after acquiring an additional 2,770 shares during the period. Institutional investors own 85.50% of the company’s stock.

Insider Transactions at LifeStance Health Group

In other news, Director Robert Bessler sold 894,337 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares in the company, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the transaction, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at approximately $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 14,629,850 shares of company stock valued at $154,952,012 over the last quarter. 3.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

LFST has been the subject of several research analyst reports. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. KeyCorp upped their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Barclays upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Canaccord Genuity Group lifted their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen raised shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, LifeStance Health Group has a consensus rating of “Moderate Buy” and an average target price of $12.12.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $12.42 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of 95.55 and a beta of 1.14. LifeStance Health Group, Inc. has a 12-month low of $4.77 and a 12-month high of $12.76. The stock’s 50-day moving average price is $10.39 and its 200-day moving average price is $8.23.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm’s revenue was up 26.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.01) earnings per share. Equities research analysts predict that LifeStance Health Group, Inc. will post 0.15 EPS for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.